Nuvo Announces 2009 second quarter financi...(xpose patients to potentially serious sy...),Health

Date:8/7/2009

xpose patients to potentially serious systemic side effects such as gastrointestinal bleeding and cardiovascular risks, Nuvo's clinical trials suggest that some of these systemic side effects occur less frequently with topically applied Pennsaid. There are more than 27 million Americans suffering from osteoarthritis and the United States market for this condition is estimated at US$4 billion annually.

About Nuvo Research Inc.

Nuvo is focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies. Nuvo's lead product is Pennsaid, a topical NSAID used for the treatment of osteoarthritis of the knee. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of topical and transdermal products targeting a variety of indications.

Nuvo is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany and a research and development center in San Diego, California. For more information, please visit www.nuvoresearch.com.

These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report, as well as in the Company's Annual Information Form for the year ended December 31, 2008. The Company disclaims a
'/>"/>

SOURCE Nuvo Research Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. GeoVax Labs, Inc. Announces Six Month 2009 Financial Results and Provides Operational Update
2. NATB Announces Partnership With Ronald McDonald House Charities(R)
3. LCA Announces More Requests for Bids on Lung Cancer Research Programs Funded Through the Department of Defense
4. ThermoGenesis Announces Launch of Res-Q System; New Device Expands Companys Presence in Bone Marrow Sector
5. Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results
6. AMN Healthcare Announces Second Quarter 2009 Results
7. IRIDEX Announces Second Quarter 2009 Conference Call and Release Date
8. NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions
9. ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program
10. Feline Pine Announces National Take Your Cat to the Vet Day August 22
11. MAP Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock